Thyreotropin levels in diabetic patients on metformin treatment

European Journal of Endocrinology

Volumn 167, Issue 2, 2012, Pages 261-265

  Cappelli, Carlo ^a   Rotondi, Mario ^b   Pirola, Ilenia ^a   Agosti, Barbara ^c   Formenti, Annamaria ^a   Zarra, Emanuela ^c   Valentini, Umberto ^c   Leporati, Paola ^b   Chiovato, Luca ^b   Castellano, Maurizio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; METFORMIN; THYROID PEROXIDASE ANTIBODY; THYROTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THYROTROPIN BLOOD LEVEL;

ADULT; AGED; AUTOANTIBODIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOTHYROIDISM; MALE; METFORMIN; MIDDLE AGED; POLYPHARMACY; RETROSPECTIVE STUDIES; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 84864369553     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0225     Document Type: Article

References (23)

1. Wild S, Roglic G, Green A, Sicree R & King H. Global prevalence of diabetes. Diabetes Care 2004 27 1047-1053. (doi:10.2337/ diacare.27.5.1047)
2. Canaris GJ, Manowitz NR, Mayor G & Ridgway EC. The Colorado thyroid disease prevalence study. Archives of Internal Medicine 2000 160 526-534. (doi:10.1001/archinte.160.4.526)
3. Perros P, McCrimmon RJ, Shaw G & Frier BM. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabetic Medicine 1995 12 622-627. (doi:10.1111/j.1464-5491.1995.tb00553.x)
4. Kordonouri O, Klinghammer A, Lang EB, Grüters-Kieslich A, Grabert M & Holl RW. Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey. Diabetes Care 2002 25 1346-1350. (doi:10.2337/diacare.25.8.1346)
5. Wu P. Thyroid disorders and diabetes. It is common for a person to be affected by both thyroid disease and diabetes. Diabetes Self-management 2007 24 (80-82) 85-87.
6. Feely J & Isles TE. Screening for thyroid dysfunction in diabetics. BMJ 1979 1 1678. (doi:10.1136/bmj.1.6179.1678)
7. Bloomagarden ZT. Approaches to treatment of type 2 diabetes. Diabetes Care 2008 31 1697-1703. (doi:10.2337/dc08-zb08)
8. Shwarts S, Fonseca V, Berner B, Cramer M, Chiang Y-K & Lewin A. Efficacy, tolerability, and safety of a novel once-daily extendedrealise metformin in patients with type 2 diabetes. Diabetes Care 2006 29 759-764. (doi:10.2337/diacare.29.04.06.dc05-1967)
9. Abdelghaffar S & Attia A. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database of Systematic Reviews 2009 21 CD006691. (doi:10.1002/14651858.CD006691.pub2)
10. Moon RJ, Bascombe LA & Holt RI. The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes, Obesity & Metabolism 2007 9 143-145. (doi:10.1111/j.1463-1326.2006.00599.x)
11. Vigersky RA, Filmore-Nassar A & Glass AR. Thyreotropin suppression by metformin. Journal of Clinical Endocrinology and Metabolism 2006 91 225-227. (doi:10.1210/jc.2005-1210)
12. Isidro ML, Penìn MA, Nemina R & Cordido F. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroidism on thyroxine replacement therapy. Endocrine 2007 32 79-82. (doi:10.1007/s12020-007-9012-3)
13. Cappelli C, Rotondi M, Pirola I, Agosti B, Gandossi E, Valentini U, De Martino E, Cimino A, Agabiti Rosei E & Castellano M. TSH-lowering effect of metformin in type 2 diabetic patients. Diabetes Care 2009 32 1589-1590. (doi:10.2337/dc09-0273)
14. Morteza Taghavi S, Rokni H & Fatemi S. Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. Diabetes & Vascular Disease Research 2011 8 47-48. (doi:10.1177/1479164110391917)
15. Rotondi M, Cappelli C, Magri F, Botta R, Dionisio R, Iacobello C, De Cata P, Nappi RE, Castellano M & Chiovato L. Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. Clinical Endocrinology 2011 75 378-381. (doi:10.1111/j.1365-2265.2011.04042.x)
16. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Safety: an International Journal of Medical Toxicology and Drug Experience 2005 28 601-631. (doi:10.2165/00002018- 200528070-00004)
17. Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ & Stehouwer CD. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. Journal of Internal Medicine 2003 254 455-463. (doi:10.1046/j.1365-2796.2003.01213.x)
18. Duntas LH, Orgiazzi J & Brabant G. The interface between thyroid and diabetes mellitus. Clinical Endocrinology 2011 75 1-9. (doi:10.1111/j.1365-2265. 2011.04029.x)
19. Lim CT, Kola B & Korbonits M. AMPK as a mediator of hormonal signalling. Journal of Molecular Endocrinology 2010 44 87-97. (doi:10.1677/JME-09-0063)
20. López M, Varela L, Vázquez MJ, Rodríguez-Cuenca S, González CR, Velagapudi VR, Morgan DA, Schoenmakers E, Agassandian K, Lage R, Martínez de Morentin PB, Tovar S, Nogueiras R, Carling D, Lelliott C, Gallego R, Oresic M, Chatterjee K, Saha AK, Rahmouni K, Diéguez C & Vidal-Puig A. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nature Medicine 2010 16 1001-1008. (doi:10.1038/nm.2207)
21. Wiersinga WM, Chopra IJ & Chua Teco GN. Inhibition of nuclear T3 binding by fatty acids. Metabolism 1988 37 996-1002. (doi:10.1016/0026-0495(88) 90159-X)
22. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt- Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA & Stockigt JR; Guidelines Committee, National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003 13 3-126. (doi:10.1089/ 105072503321086962)
23. Wartofsky L & Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. Journal of Clinical Endocrinology and Metabolism 2005 90 5483-5488. (doi:10.1210/jc.2005-0455)